Rocket Pharmaceuticals (RCKT) Stock Analysis & Winston Score

Rocket Pharmaceuticals is a biotechnology company that develops gene therapies for rare, life-threatening genetic diseases. Its treatments are designed to fix faulty genes in patients — mostly children — who have conditions like Fanconi anemia, leukocyte adhesion deficiency, and Danon disease. The company focuses on diseases that have few or no other treatment options. Rocket makes money by developing these therapies and seeking regulatory approval to sell them, though it has not yet generated meaningful product revenue. It operates primarily in the United States and conducts clinical trials globally. Because gene therapy aims to provide a one-time fix rather than ongoing treatment, the potential market per patient is large, but so is the cost and complexity of development. The main risk is that clinical-stage biotech companies burn through cash quickly, and Rocket must successfully advance its pipeline through trials and win FDA approval to survive — a process that is expensive, uncertain, and time-consuming.